Literature DB >> 24813091

Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET for detecting tumor repopulation during fractionated radiotherapy of human FaDu squamous cell carcinoma in nude mice.

Jin-Bo Yue1, Jia Yang2, Jing Liu3, Jason Lee4, Alvin R Cabrera4, Xin-Dong Sun1, Guang-Hui Bai5, Yu-Hui Li6, Jin-Ming Yu7.   

Abstract

BACKGROUND AND
PURPOSE: FaDu human squamous cell carcinoma (FaDu-hSCC) demonstrates accelerated tumor repopulation during fractionated irradiation with pathological validation (Ki-67 and BrdUrd makers) in a xenograft model system. However, these and other functional assays must be performed ex vivo and post hoc. We propose a novel, in vivo, real-time assay utilizing (18)F-FLT PET.
MATERIAL AND METHODS: Nude mice with FaDu-hSCC were irradiated with 12 or 18 fractions of 1.8 Gy ([Dm]=3.0 Gy), either daily or every second day. (18)F-FLT micro-PET scans were performed at different time points, FLT parameters (SUVmax, SUVmean, and T/NT) were measured. Tumor sections were stained for Ki-67 and BrdUrd, a labeling index (LI) was calculated. Imaging-pathology correlation was determined by comparing FLT parameters and immunohistochemical results.
RESULTS: Measured SUVmax, SUVmean and T/NT decreased significantly after daily irradiation with 12 fractions in 12 days (P<0.05) and 18 fractions in 18 days (P<0.05). In contrast, these parameters increased in mice treated with 12 fractions in 24 days (P>0.05) and 18 fractions in 36 days (P>0.05), suggesting accelerated repopulation. Similarly, Ki-67 and BrdUrd LIs demonstrated significant decreases with daily irradiation (P<0.05), and increases with every-second-day irradiation (P>0.05). (18)F-FLT parameters correlated strongly with proliferation markers (r(2): 0.679-0.879, P<0.001).
CONCLUSIONS: (18)F-FLT parameters were in good agreement with Ki-67 and BrdUrd Li. These results may support a potential role for (18)F-FLT PET in real-time detection of tumor repopulation during fractionated radiotherapy.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  (18)F-fluorothymidine PET; Fractionated radiotherapy; Immunohistochemistry; Proliferation; Tumor repopulation

Mesh:

Substances:

Year:  2014        PMID: 24813091     DOI: 10.1016/j.radonc.2014.04.002

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Spatial Concordance of Tumor Proliferation and Accelerated Repopulation from Pathologic Images to 3'-[18F]Fluoro-3'-Deoxythymidine PET Images: a Basic Study Guided for PET-Based Radiotherapy Dose Painting.

Authors:  Chengming Li; Xiaoli Zhang; Linlin Pang; Yong Huang; Yongsheng Gao; Xindong Sun; Jinming Yu; Xue Meng
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

Review 2.  PET in the management of locally advanced and metastatic NSCLC.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

3.  Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.

Authors:  Jing Liu; Chengqiang Li; Man Hu; Jie Lu; Xiaorong Shi; Ligang Xing; Xindong Sun; Zheng Fu; Jinming Yu; Xue Meng
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

Review 4.  Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.

Authors:  Sonja Schelhaas; Kathrin Heinzmann; Vikram R Bollineni; Gerbrand M Kramer; Yan Liu; John C Waterton; Eric O Aboagye; Anthony F Shields; Dmitry Soloviev; Andreas H Jacobs
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

5.  In-vivo Comparison of 18F-FLT uptake, CT Number, Tumor Volume in Evaluation of Repopulation during Radiotherapy for Lung cancer.

Authors:  Xiaoli Zhang; Jinming Yu; Chengming Li; Xindong Sun; Xue Meng
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.